AP1821A - New process for the synthesis of ivabradine and additional salts thereof with a pharmaceutically acceptable acid - Google Patents

New process for the synthesis of ivabradine and additional salts thereof with a pharmaceutically acceptable acid

Info

Publication number
AP1821A
AP1821A AP2005003222A AP2005003222A AP1821A AP 1821 A AP1821 A AP 1821A AP 2005003222 A AP2005003222 A AP 2005003222A AP 2005003222 A AP2005003222 A AP 2005003222A AP 1821 A AP1821 A AP 1821A
Authority
AP
ARIPO
Prior art keywords
ivabradine
synthesis
pharmaceutically acceptable
acceptable acid
new process
Prior art date
Application number
AP2005003222A
Other languages
English (en)
Other versions
AP2005003222A0 (en
Inventor
Jean-Michel Lerestif
Jean-Pierre Lecouve
Jean-Claude Souvie
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34941959&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP1821(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of AP2005003222A0 publication Critical patent/AP2005003222A0/xx
Priority to TW095136786A priority Critical patent/TW200817334A/zh
Application granted granted Critical
Publication of AP1821A publication Critical patent/AP1821A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • E—FIXED CONSTRUCTIONS
    • E01—CONSTRUCTION OF ROADS, RAILWAYS, OR BRIDGES
    • E01C—CONSTRUCTION OF, OR SURFACES FOR, ROADS, SPORTS GROUNDS, OR THE LIKE; MACHINES OR AUXILIARY TOOLS FOR CONSTRUCTION OR REPAIR
    • E01C11/00—Details of pavings
    • E01C11/16—Reinforcements
    • E01C11/165—Reinforcements particularly for bituminous or rubber- or plastic-bound pavings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Structural Engineering (AREA)
  • Civil Engineering (AREA)
  • Architecture (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AP2005003222A 2004-04-13 2005-02-07 New process for the synthesis of ivabradine and additional salts thereof with a pharmaceutically acceptable acid AP1821A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW095136786A TW200817334A (en) 2005-02-07 2006-10-03 New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0403830A FR2868777B1 (fr) 2004-04-13 2004-04-13 Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable

Publications (2)

Publication Number Publication Date
AP2005003222A0 AP2005003222A0 (en) 2005-03-31
AP1821A true AP1821A (en) 2008-01-21

Family

ID=34941959

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2005003222A AP1821A (en) 2004-04-13 2005-02-07 New process for the synthesis of ivabradine and additional salts thereof with a pharmaceutically acceptable acid

Country Status (43)

Country Link
US (2) US7176197B2 (xx)
EP (1) EP1589005B1 (xx)
JP (2) JP4515934B2 (xx)
KR (1) KR100677019B1 (xx)
CN (1) CN1305856C (xx)
AP (1) AP1821A (xx)
AR (1) AR047745A1 (xx)
AT (1) ATE358123T1 (xx)
AU (1) AU2005200861B2 (xx)
BR (1) BRPI0500585B8 (xx)
CA (1) CA2496723C (xx)
CO (1) CO5670092A1 (xx)
CR (2) CR7691A (xx)
CU (1) CU23465B7 (xx)
CY (1) CY1106597T1 (xx)
DE (1) DE602005000765T2 (xx)
DK (1) DK1589005T3 (xx)
EA (1) EA007745B1 (xx)
EC (1) ECSP055610A (xx)
ES (1) ES2285651T3 (xx)
FR (1) FR2868777B1 (xx)
GE (1) GEP20074138B (xx)
HK (1) HK1080362B (xx)
HR (1) HRP20070246T5 (xx)
IL (1) IL167013A (xx)
MA (1) MA27600A1 (xx)
ME (1) ME01396B (xx)
MX (1) MXPA05003694A (xx)
MY (1) MY141194A (xx)
NI (1) NI200500031A (xx)
NO (1) NO329807B1 (xx)
NZ (1) NZ538326A (xx)
OA (1) OA12913A (xx)
PL (1) PL1589005T3 (xx)
PT (1) PT1589005E (xx)
RS (1) RS50511B (xx)
SA (1) SA05260016B1 (xx)
SG (1) SG116575A1 (xx)
SI (1) SI1589005T1 (xx)
UA (1) UA80834C2 (xx)
UY (1) UY28759A1 (xx)
WO (1) WO2005110993A1 (xx)
ZA (1) ZA200501466B (xx)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868775B1 (fr) * 2004-04-13 2008-04-11 Servier Lab Nouveau procede de synthese de derives de la 1,3,4,5- tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2868776B1 (fr) * 2004-04-13 2008-04-18 Servier Lab Nouveau procede de synthese de derives de la 1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2894826B1 (fr) * 2005-12-21 2010-10-22 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent
EP2097383B1 (en) 2006-11-30 2012-02-08 Cadila Healthcare Limited Process for preparation of ivabradine hydrochloride
WO2008125006A1 (fr) * 2007-04-12 2008-10-23 Utopharm (Shanghai) Co., Ltd Procédés de préparation du chlorhydrate d'ivabradine et de sa forme cristalline stable
US8212026B2 (en) 2007-05-30 2012-07-03 Ind-Swift Laboratories Limited Process for the preparation of ivabradine hydrochloride and polymorph thereof
SI22750A (sl) * 2008-04-07 2009-10-31 Krka D.D. Ivabradin hidrobromid
FR2932800B1 (fr) * 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2933975B1 (fr) 2008-07-17 2011-02-18 Servier Lab Nouveau procede de preparation de benzocyclobutenes fonctionnalises,et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable.
FR2935381B1 (fr) 2008-08-29 2010-12-17 Servier Lab Nouveau procede de resolution des enantiomerees du (3,4-dimethoxy-bicyclo°4.2.0!octa-1,3,5-trien-7-yl)nitrile et application a la synthese de l'ivabradine
CN101723897B (zh) * 2008-10-31 2011-11-16 齐鲁制药有限公司 伊伐布雷定的合成方法
WO2010072409A1 (en) 2008-12-22 2010-07-01 Krka, D. D., Novo Mesto Process for preparation of ivabradine
FR2940287B1 (fr) * 2008-12-24 2010-12-24 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable.
CN101768116B (zh) * 2008-12-29 2014-06-18 北京德众万全药物技术开发有限公司 一种伊伐布雷定的制备方法
CN101768117B (zh) * 2008-12-29 2014-05-07 北京德众万全药物技术开发有限公司 一种盐酸伊伐布雷定晶型及其制备方法
FR2941695B1 (fr) 2009-02-04 2011-02-18 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
ME00986B (me) * 2009-03-31 2012-06-20 Servier Lab Novi postupak sinteze ivabradina i njegovih adicionih soli sa farmaceutski prihvatljivom kiselinom
FR2943667B1 (fr) * 2009-03-31 2011-05-06 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable.
WO2010128525A2 (en) 2009-05-04 2010-11-11 Dinesh Shantilal Patel A formulation of ivabradine for treating the cardiovascular disease
EP2902384B1 (en) 2010-02-12 2017-11-08 KRKA, D.D., Novo Mesto Form of ivabradine hydrochloride
FR2956401B1 (fr) * 2010-02-17 2012-02-03 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
WO2011104723A2 (en) * 2010-02-23 2011-09-01 Ind-Swift Laboratories Limited Acid addition salts of ivabradine and preparation thereof
HUP1000245A2 (en) * 2010-05-07 2011-11-28 Richter Gedeon Nyrt Industrial process for the production ivabradin salts
TWI499587B (zh) * 2010-06-03 2015-09-11 Jiangsu Hengrui Medicine Co 硫酸伊伐佈雷定及其ｉ型結晶的製備方法
US20130084335A1 (en) 2010-06-14 2013-04-04 Ratiopharm Gmbh Ivabradine-containing pharmaceutical composition
WO2012025940A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
FR2971507B1 (fr) * 2011-02-14 2013-01-18 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
CN102304088B (zh) * 2011-07-07 2013-06-19 石药集团欧意药业有限公司 一种伊伐布雷定化合物、制备方法及其药物组合物
EP2726462B1 (en) 2011-08-02 2017-03-22 Sandoz AG Acetone solvate of ivabradine hydrochloride
EP2589594A1 (en) 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
WO2013064427A1 (en) 2011-11-04 2013-05-10 Synthon Bv A process for making crystalline delta-form of ivabradine hydrochloride
US9120755B2 (en) 2011-11-14 2015-09-01 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
FR2984320B1 (fr) * 2011-12-20 2013-11-29 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2984319B1 (fr) * 2011-12-20 2013-12-27 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2986804A1 (fr) * 2012-02-09 2013-08-16 Servier Lab Procede de synthese enzymatique de l'acide (7s) 3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene 7-carboxylique ou de ses esters, et application a la synthese de l'ivabradine et de ses sels
FR2988720B1 (fr) * 2012-03-27 2014-03-14 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2993561B1 (fr) * 2012-07-17 2014-10-31 Servier Lab Procede de synthese enzymatique de la (7s)-1-(3,4-dimethoxy bicyclo[4.2.0]octa-1,3,5-triene 7-yl) n-methyl methanamine, et application a la synthese de l'ivabradine et de ses sels
CN103848789B (zh) * 2012-11-29 2016-05-18 江苏恒瑞医药股份有限公司 一种伊伐布雷定的制备方法
CN103012268B (zh) * 2013-01-05 2015-02-25 江苏宇田生物医药科技有限公司 一种伊伐布雷定制备方法
WO2014114341A1 (en) 2013-01-24 2014-07-31 Synthon Bv Process for making ivabradine
ITMI20130684A1 (it) * 2013-04-24 2014-10-25 Chemo Res S L Nuovo polimorfo del cloridrato di ivabradina e metodo per la sua preparazione
EP2781509B2 (en) 2013-03-19 2023-06-14 Chemo Research, S.L. New polymorph of ivabradine hydrochloride and method for its preparation
ITMI20130416A1 (it) * 2013-03-19 2014-09-20 Chemo Res S L Nuovo polimorfo del cloridrato di ivabradina e metodo per la sua preparazione
CZ305096B6 (cs) 2013-10-02 2015-04-29 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
ES2672472T3 (es) 2013-12-12 2018-06-14 Synthon Bv Composición farmacéutica que comprende ivabradina amorfa
CN103864690B (zh) * 2014-01-06 2016-09-14 北京莱瑞森医药科技有限公司 伊伐布雷定盐酸盐的s晶型、其制备方法和药物组合物
EP2774606B1 (en) 2014-02-14 2019-01-30 Synthon B.V. Pharmaceutical composition comprising ivabradine hydrochloride polymorph IV
CN103880748B (zh) * 2014-04-03 2015-09-16 南京正大天晴制药有限公司 一种盐酸伊伐布雷定结构类似物及其制备方法和应用
CZ305436B6 (cs) 2014-07-10 2015-09-16 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
WO2016102423A1 (en) 2014-12-22 2016-06-30 Ratiopharm Gmbh Composition comprising ivabradine in a dissolved form
EP3101010A1 (en) 2015-06-03 2016-12-07 Urquima S.A. New method for the preparation of highly pure ivabradine base and salts thereof
CN107056706B (zh) * 2015-12-21 2020-05-05 江苏恒瑞医药股份有限公司 一种用于制备盐酸伊伐布雷定α晶型的方法
EP3366282A1 (en) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
TR201703066A2 (tr) 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3615052B1 (en) 2017-04-27 2023-01-25 The University of Hong Kong Use of hcn inhibitors for treatment of cancer
US20230181472A1 (en) 2018-10-30 2023-06-15 Amgen Inc. Process of making ivabradine hydrochloride drug product
IT202000025312A1 (it) 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L Processi per la preparazione di polimorfi di ivabradina hcl
CN115286577B (zh) * 2022-08-25 2023-10-20 江苏永安制药有限公司 一种盐酸伊伐布雷定及其中间体的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0534859A1 (fr) * 1991-09-27 1993-03-31 Adir Et Compagnie 3-Benzazépin-zones substituées par un groupe benzocyclobutyl- ou indanyl-alkyl-amino-alkyle, utiles dans le traitement des affections cardiovasculaires

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3119874A1 (de) 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
DE3418270A1 (de) 1984-05-17 1985-11-21 Dr. Karl Thomae Gmbh, 7950 Biberach Neue aminotetralinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3519735A1 (de) * 1985-06-01 1986-12-04 Dr. Karl Thomae Gmbh, 7950 Biberach Neue heteroaromatische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0204349A3 (de) 1985-06-01 1990-01-03 Dr. Karl Thomae GmbH Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
FR2834896B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'ivabradine
FR2868776B1 (fr) * 2004-04-13 2008-04-18 Servier Lab Nouveau procede de synthese de derives de la 1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2868775B1 (fr) * 2004-04-13 2008-04-11 Servier Lab Nouveau procede de synthese de derives de la 1,3,4,5- tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0534859A1 (fr) * 1991-09-27 1993-03-31 Adir Et Compagnie 3-Benzazépin-zones substituées par un groupe benzocyclobutyl- ou indanyl-alkyl-amino-alkyle, utiles dans le traitement des affections cardiovasculaires

Also Published As

Publication number Publication date
SG116575A1 (en) 2005-11-28
GEP20074138B (en) 2007-06-25
CU23465B7 (es) 2009-12-17
PT1589005E (pt) 2007-06-18
DE602005000765D1 (de) 2007-05-10
JP4515934B2 (ja) 2010-08-04
AU2005200861B2 (en) 2010-07-15
PL1589005T3 (pl) 2007-07-31
FR2868777A1 (fr) 2005-10-14
HK1080362B (zh) 2007-07-20
ECSP055610A (es) 2006-03-01
JP2005298480A (ja) 2005-10-27
CA2496723C (fr) 2010-05-25
HK1080362A1 (en) 2006-04-28
US20070135411A1 (en) 2007-06-14
KR100677019B1 (ko) 2007-02-01
CN1305856C (zh) 2007-03-21
CO5670092A1 (es) 2006-08-31
SI1589005T1 (sl) 2007-08-31
MXPA05003694A (es) 2006-01-24
US7867994B2 (en) 2011-01-11
BRPI0500585A (pt) 2005-11-16
NO20050884D0 (no) 2005-02-18
EA007745B1 (ru) 2006-12-29
CY1106597T1 (el) 2012-01-25
CA2496723A1 (fr) 2005-10-13
NO20050884L (no) 2005-10-14
ME01396B (me) 2010-03-02
BRPI0500585B1 (pt) 2020-11-03
JP4848449B2 (ja) 2011-12-28
NO329807B1 (no) 2010-12-20
EA200500238A1 (ru) 2005-10-27
RS50511B (sr) 2010-03-02
JP2010047578A (ja) 2010-03-04
FR2868777B1 (fr) 2006-05-26
BRPI0500585B8 (pt) 2021-05-25
SA05260016B1 (ar) 2009-06-06
EP1589005B1 (fr) 2007-03-28
CR11780A (es) 2010-12-09
ATE358123T1 (de) 2007-04-15
HRP20070246T5 (en) 2008-10-31
US7176197B2 (en) 2007-02-13
DK1589005T3 (da) 2007-07-30
MA27600A1 (fr) 2005-11-01
ZA200501466B (en) 2005-11-30
HRP20070246T3 (en) 2007-08-31
NZ538326A (en) 2005-11-25
ES2285651T3 (es) 2007-11-16
AU2005200861A1 (en) 2005-10-27
IL167013A (en) 2011-08-31
UA80834C2 (en) 2007-11-12
AP2005003222A0 (en) 2005-03-31
OA12913A (en) 2006-10-13
NI200500031A (es) 2006-05-25
AR047745A1 (es) 2006-02-15
CN1683341A (zh) 2005-10-19
UY28759A1 (es) 2005-12-30
DE602005000765T2 (de) 2008-01-10
WO2005110993A1 (fr) 2005-11-24
KR20060042116A (ko) 2006-05-12
US20050228177A1 (en) 2005-10-13
EP1589005A1 (fr) 2005-10-26
CR7691A (es) 2008-09-23
MY141194A (en) 2010-03-31

Similar Documents

Publication Publication Date Title
AP1821A (en) New process for the synthesis of ivabradine and additional salts thereof with a pharmaceutically acceptable acid
ZA200501469B (en) Process for the synthesis of (1s)-4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane and addition salts thereof, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
ZA200501468B (en) Process for the synthesis of 1,3,4,5-tetrahydro-3-benzazepin-2-one compounds, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
HK1145833A1 (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
ZA200904316B (en) Process for the synthesis of 7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
IL177511A0 (en) Process for the synthesis of a cxcr4 antagonist
ZA200501467B (en) Process for the synthesis of 1,3-dihydro-2h-3-benzazepin-2-one compounds, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
PL2078025T3 (pl) Sposób syntezy klopidogrelu oraz nowe formy jego farmaceutycznie dopuszczalnych soli
HK1169827A1 (en) Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
PL1641438T3 (pl) Sposób wytwarzania amorficznej postaci leku
PL2099740T3 (pl) Sposób wytwarzania optycznie czystego R(-) salbutamolu oraz ich farmaceutycznie dopuszczalnych soli
JO2518B1 (en) A new method for the combination of ivabradine and its added salts with pharmaceutically acceptable acid